

## **Company Overview**

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the \$4 billion electrophysiology (EP) marketplace.

# **BioSig Technologies Inc. Issues 2019 Shareholder Letter** Feb 12 2019, 7:52 AM EST

## **BioSig Appoints John Kowalski to Lead Commercialization** of PURE EP

**Investor Relations** 

T: (866) 976-4784

ir@biosigtech.com

Feb 5 2019, 7:52 AM EST

# Johnson & Johnson's Biosense Webster's MaryAnn Edzards Joins BioSig

Dec 19 2018, 8:00 AM EST

## **Stock Overview**

Symbol BSGM Exchange Nasdaq

Market Cap 85.32m

**Last Price** \$5.12 **52-Week Range** \$3.2125 - \$7.875

02/15/2019 04:00 PM EST

## Management Team

## Kenneth L. Londoner, MBA

Founder, Chief Executive Officer, Chairman, and Director

### **Steve Chaussy**

Chief Financial Officer

#### Tiffini Wittwer

Chief Regulatory and Compliance Officer

#### Natasha Drapeau

**Executive Vice President** 

### John Kowalski

Vice President, Sales

#### **Amy Scott**

Vice President, Strategic Partnerships

#### **Lora Mikolaitis**

Vice President, Administration

## BioSig Technologies, Inc.

12424 Wilshire Blvd Suite 745 Los Angeles, CA 90025

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.